Standout Papers

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of c... 2021 2026 2022 2024202
  1. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial (2021)
    Martin Kankam, Michael Lund et al. The Lancet

Immediate Impact

1 by Nobel laureates 8 from Science/Nature 71 standout
Sub-graph 1 of 20

Citing Papers

Remibrutinib in Chronic Spontaneous Urticaria
2025 Standout
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025 Standout
1 intermediate paper

Works of Martin Kankam being referenced

Anti‐KIT monoclonal antibody CDX‐0159 induces profound and durable mast cell suppression in a healthy volunteer study
2022
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
2021 Standout

Author Peers

Author Last Decade Papers Cites
Martin Kankam 149 166 153 190 31 731
Sun‐Mi Kim 102 81 222 98 37 686
Gregory P. Bondy 89 130 68 110 22 757
Aurélie Claës 43 329 103 220 22 827
Yun Huang 90 173 80 156 39 618
Vanessa S. Mattevi 75 108 157 91 45 805
Chunlin Wang 131 197 194 121 58 813
Brenda H. Welter 277 117 142 96 24 695
Derek M. Culnan 221 160 140 80 21 758
Alison K. Wright 42 87 126 321 28 668
M. Labiós Gómez 161 115 267 53 17 721

All Works

Loading papers...

Rankless by CCL
2026